In recent years, advanced lung cancer inflammation index (ALI) has gained recognition as a new biomarker, combining neutrophil-to-lymphocyte ratio (NLR), serum albumin levels, as well as the body mass index (BMI) to evaluate the inflammatory as well as nutritional status of individuals with advanced lung cancer. The gene discussed is ALB; the disease is lung carcinoma.